SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Inside the new AI jobs: How companies are hiring and what they’re paying

Tenable appoints Vlad Korsunsky as CTO and Managing Director of Tenable Israel

Viola Ventures raises $250 million to back Israel’s next tech wave

Israeli tech’s dual reality: Mega deals vs. rapid AI exits

Buzz

Most popular

Daily

Weekly

1

“Younger people are getting cancer more and more. We have to make kinder medicines.”

2

Shipping giant MSC submits bid for ZIM, challenging Hapag-Lloyd in takeover race

3

ServiceNow in advanced talks to acquire Armis at around $7 billion valuation

4

The $2.3 billion mystery arms deal Israel won’t explain

5

Armis sale to ServiceNow could yield $4 billion windfall for Insight Partners

QuantHealth

4 stories about QuantHealth

Hila Karah Pitango Health

“The long-term opportunities in AI are immense for health-tech companies”

16.01.25|James Spiro, Elihay Vidal

Hila Karah, Managing Partner at Pitango HealthTech, joined CTech to share insights in the high-tech ecosystem.

Shoni Health Ventures outlines the landscape of opportunities and challenges in 2025

06.01.25|James Spiro, Elihay Vidal

CEO and Managing Partner Eran Lerer joined CTech to share insights on the year ahead and how HealthTech will be impacted.

Arnon Horev Orr Inbar

QuantHealth secures $2 million in funding from Accenture and other investors to deliver AI-powered clinical trial simulations

This announcement extends the Israeli startup’s recent $15 million Series A and comes on the back of the launch of its latest product, Katina, which provides clinical researchers with an AI-guided workflow that simulates hundreds of thousands of potential trial protocol combinations of patient groups, treatment parameters and different endpoints, to maximize the trial success probability

Arnon Horev Orr Inbar

QuantHealth announces $15 million Series A to use AI to enhance success of clinical trials

The Israeli startup’s AI platform predicts efficacy and safety of clinical trials to try and optimize trial design, and identify key response population